Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients

Movement Disorders

Volumn 15, Issue 4, 2000, Pages 613-626

  Kulisevsky, Jaime ^a   García Sánchez, Carmen ^a   Berthier, Marcelo L ^b   Barbanoj, Manel ^a   Pascual Sedano, Berta ^a   Gironell, Alexandre ^a   Estévez González, Armando ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cognition; Frontal functions; Levodopa; Parkinson's disease; Pergolide

Indexed keywords

DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LORAZEPAM; PERGOLIDE;

ADULT; AGED; ANXIETY; APTITUDE TEST; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPTH PERCEPTION; DOPAMINERGIC ACTIVITY; DROWSINESS; FEMALE; HUMAN; LEARNING; LONG TERM MEMORY; MALE; MOTOR ACTIVITY; NAUSEA; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEMANTICS; SHORT TERM MEMORY; TREATMENT OUTCOME; VERBAL MEMORY; VISUAL HALLUCINATION; VISUAL MEMORY;

AGED; ANTIPARKINSON AGENTS; COGNITION DISORDERS; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PERGOLIDE;

EID: 0343962283     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F     Document Type: Article

References (92)

1. Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from description to theory [Review]. Trends Neurosci 1990; 13:21-29.
2. Warburton JW. Memory disturbance and the Parkinson syndrome. Br J Med Psychol 1967;40:169-171.
3. Wilson RS, Kaszniak AW, Klawans HL, Garron DC. High speed memory scanning in parkinsonism. Cortex 1980;16:67-72.
4. Boller F, Passafiume D, Keefe NC, Rogers K, Morrow L, Kim Y. Visuospatial impairment in Parkinson's disease: role of perceptual and motor factors. Arch Neurol 1984;41:485-490.
5. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 1989;27:1329-1343.
6. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain 1986;109:845-883.
7. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988;111:299-321.
8. Bowen FP, Kamienny MA, Burns MM, Yahr M. Parkinsonism: effects of L-dopa on concept formation. Neurology 1975;25:701-704.
9. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992;107:394-404.
10. Growdon JH, Kieburtz K, McDermott MP, Panisst M, Friedman JH. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Neurology 1998;50:1327-1331.
11. Pillon B, Dubois B, Bonnet A-M, et al. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15 objects test. Neurology 1989;39:762-768.
12. Kulisevsky J, Avila A, Barbanoj M, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-2132.
13. Rogers D, Lees AJ, Smith E, Trimble M, Stern GM. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness: an experimental study. Brain 1987;110:761-776.
14. Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN. Cognitive concomitants of dopamine system stimulation in parkinsonian patients. J Neurol Neurosurg Psychiatry 1987;50:1192-1196.
15. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 1992;115:1701-1725.
16. Poewe W, Berger W, Benke TH, Schelosky L. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991;29:670-673.
17. Riklan M, Whelihan W, Cullinan T. Levodopa and psychometric test performance in parkinsonism: 5 years later. Neurology 1976; 26:173-179.
18. Portin R, Rinne UK. Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's Disease: Current Progress, Problems and Management. Amsterdam: Elsevier North-Holland, 1980:271-304.
19. Girotti F, Carella F, Grassi MP, Soliveri P, Marano R, Caraceni T. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry 1986;49:657-660.
20. Lees AJ. When did Ray Kennedy's Parkinson's begin? Mov Disord 1992;7:110-116.
21. Schneider JS, Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995;4:245-255.
22. Schneider JS, Van Velson M, Menzaghi F, Lloyd GK. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 1998;43:311-317.
23. Lezak M. Neuropsychological Assessment, 3rd ed. New York, NY: Oxford University Press, 1995.
24. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997;49(suppl 1):S34-S48.
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
26. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, DC: American Psychiatric Association, 1994.
28. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-571.
29. Fahn S, Elston RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease, vol 2. New York, NY: MacMillan, 1987: 153-163.
30. McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev 1995;5:203-221.
31. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945;16:87-95.
32. Benton AL. The Revised Visual Retention Test, 4th ed. New York, NY: Psychological Corp, 1974.
33. Rey A. L'examen Clinique en Psychologie. Paris: Presses Universitaires de France, 1964.
34. Crawford JR, Stewart LE, Moore JW. Demonstrations on savings on the AVLT and development of a parallel form. J Clin Exp Neuropsychol 1989;11:975-981.
35. Lee GP, Loring DW, Thompson JL. Construct validity of material specific memory measures following unilateral temporal lobe ablations. Psychological Assessment 1989;1:192-197.
36. Halstead WC. Brain and Intelligence: a Quantitative Study of the Frontal Lobes. Chicago, IL: University of Chicago Press, 1947.
37. Kelland DZ, Lewis R, Gurevitch D. Evaluation of the repeatable cognitive-perceptual-motor battery: reliability, validity and sensitivity to Diazepam [Abstract]. J Clin Exp Neuropsychol 1992;14:65.
38. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. Administration, Norms and Comments. New York, NY: Oxford University Press, 1991.
39. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
40. Luria AR. The frontal lobes and the regulation of behavior. In: Pribram KH, Luria AR, eds. Psychophysiology of the Frontal Lobes. New York, NY: Academic Press, 1973.
41. Christensen AL. Luria's Neuropsychological Investigation. Madrid: Pablo del Rio, 1974.
42. Benton AL, Hamsher K de S. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates, 1989.
43. Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol 1988;45:1194-1199.
44. Starkstein SE, Esteguy M, Berthier ML, García H, Leiguarda L. Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:338-340.
45. Pullman SL, Watts RL, Juncos JL, Chase TN, Sanes JN. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 1988;38:249-254.
46. Malapani C, Pillon B, Dubois B, Agid Y. Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunction. Neurology 1994;44:319-326.
47. Prasher D, Findley L. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation. J Neurol Neurosurg Psychiatry 1991;54:603-609.
48. Taylor AE, Saint-Cyr JA, Lang AE. Parkinson's disease. Cognitive changes in relation to treatment response. Brain 1987;110:35-51.
49. Levin BE, Llabre MM, Weiner WS. Cognitive impairments associated with early Parkinson's disease. Neurology 1989;39:557-561.
50. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated, Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122.
51. Halgin R, Riklan M, Misiak H. Levodopa, parkinsonism and recent memory. J Nerv Ment Dis 1977;164:268-272.
52. Marsh GG, Markham CM, Ansel R. Levodopa's awakening effect on patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:209-218.
53. Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984;47:454-465.
54. Cooper JA, Sagar HJ. Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol 1993;15:713-731.
55. Stam CJ, Visser SL, Op de Coul AW, et al. Disturbed regulation of attention in Parkinson's disease. Brain 1993;116:1139-1158.
56. López-Villegas D, Kulisevsky J, Deus J, et al. Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. Arch Neurol 1996;53:251-256.
57. Sass KJ, Buchanan CP, Westerveld M, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurol 1995;52:680-686.
58. Wilson FA, Scalaidhe SPO, Goldman-Rakic PS. Dissociation of object and spatial processing domains in primate prefrontal cortex. Science 1993;260:1955-1958.
59. Brown RG, Marsden CD. Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. Brain 1991;114:215-231.
60. Dalrymple-Alford JC, Kalders AS, Jones RD, Watson RW. A central executive deficit in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:360-367.
61. Roberts AC, De Salvia MA, Wilkinson LS, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 1994;14:2531-2544.
62. Owen AM, Beksinska M, James M, et al. Dopamine dependent spatial working memory deficits in Parkinson's disease [Abstract]. Society for Neuroscience Abstracts 1991;17:261.
63. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992;115: 1727-1751.
64. Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW. Contrasting mechanisms of impaired attentional shifting in patients with frontal lobe damage or Parkinson's disease. Brain 1993;116:1159-1179.
65. Owen AM, Sahakian B, Hodges JR, et al. Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease. Neuropsychology 1995;9:126-140.
66. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-932.
67. Shimamura AP, Janowsky JS, Squire LR. What is the role of frontal lobe damage in memory disorders? In: Levin HS, Eisenberg HM, Benton AL, eds. Frontal Lobe Function and Dysfunction. New York, NY: Oxford University Press, 1991:173-195.
68. Stuss DT, Alexander MP, Palumbo CL, Buckle L, Sayer L, Pogue J. Organizational strategies of patients with unilateral or bilateral frontal lobe injury in word list learning tasks. Neuropsychology 1994;8:355-373.
69. Hall RD, Bloom FE, Olds J. Neuronal and neurochemical substrates of reinforcement. Neurosci Res Prog Bull 1977;15:131-134.
70. Routtenberg A. The reward system of the brain. Sci Am 1978;239: 154-164.
71. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995;376: 572-575.
72. Watanabe M. Reward expectancy in primate prefrontal neurons. Nature 1996;382:629-632.
73. Baddeley A, Wilson B. Amnesia, autobiographical memory, and confabulation. In: Rubin DC, ed. Autobiographical Memory. Cambridge, MA: Cambridge University Press, 1986:225-252.
74. Goldman-Rakic PS. Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 1995;93:13473-13480.
75. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' function. Prog Brain Res 1990;85:119-146.
76. Javoy-Agid F, Agid Y. Is the mesocortical dopamine system involved in Parkinson's disease? Neurology 1980;30:1326-1330.
77. Narabayashi H. The neural mechanism and progressive nature of symptoms of Parkinson's disease - based on clinical neurophysiological and morphological studies. J Neural Transm [P-D Sect] 1995;10:63-75.
78. Nutt JG, Holford HG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
79. Ekesbo A, Rydin E, Tostenson R, Sydow O, Låengström B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999;52:120-125.
80. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems [Review]. Neurology 1993;43(suppl 6):23S-27S.
81. Albercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
82. Van Horne C, Hoffer BJ, Strömberg I, Gerhardt GA. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J Pharmacol Exp Ther 1992;263: 1285-1292.
83. Murphy BL, Arnsten AFT, Goldman-Rakic PS, Roth RH. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 1996;93:325-1329.
84. Goldstein M, Lieberman A, Lew JY, et al. Interaction of pergolide with central dopamine receptors. Proc Natl Acad Sci USA 1980; 77:3725-3728.
85. Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian Rhesus monkeys. Mov Disord 1994;9:664-672.
86. Grondin R, Van Diep D, Grégoire L, Bédard PJ. D1 receptor blockade improves L-dopa induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999;52:771-776.
87. Fuxe K, Agnati LF, Kohler C, et al. Characterisation of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. J Neural Transm 1981;51:3-37.
88. Pezzoli G, Martignoni E, Pachetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, cross-over, controlled study. Mov Disord 1994;9:431-436.
89. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45:S13-21.
90. Arnsten AFT, Cai JX, Steere JC, Goldman-Rakic PS. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosci 1995;15:3429-3439.
91. Luciana M, Collins PF, Depue RA. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 1998;8:218-226.
92. Müller U, von Cranon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 1998;18:2720-2728.